These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15229033)

  • 1. Effect of raloxifene on urinary incontinence: a randomized controlled trial.
    Lowder JL; Weber AM
    Obstet Gynecol; 2004 Jul; 104(1):197-8; author reply 198. PubMed ID: 15229033
    [No Abstract]   [Full Text] [Related]  

  • 2. Clarification needed for raloxifene use.
    Reinders M
    Can Fam Physician; 2000 Nov; 46():2185. PubMed ID: 11143573
    [No Abstract]   [Full Text] [Related]  

  • 3. Raloxifene and its role in breast cancer prevention.
    Eng-Wong J; Zujewski JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):523-32. PubMed ID: 15270657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term effect of raloxifene on the genitourinary tract.
    Sharma S; Albertazzi P; Bottazzi M
    Climacteric; 2007 Jun; 10(3):244-8. PubMed ID: 17487651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evidence-based medicine and drug selection of osleoporosis prevention after menopause].
    Xu L
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):265-6. PubMed ID: 15059503
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2056-7. PubMed ID: 15879827
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study.
    Cicinelli E; Pinto V; Tinelli R; Saliani N; De Leo V; Cianci A
    Fertil Steril; 2007 Sep; 88(3):698-701. PubMed ID: 17678902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life.
    Palomba S; Orio F; Russo T; Falbo A; Amati A; Zullo F
    Fertil Steril; 2004 Aug; 82(2):480-2. PubMed ID: 15302308
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.
    Hadjadj S; Gourdy P; Zaoui P; Guerci B; Roudaut N; Gautier JF; Chabin M; Mauco G; Ragot S;
    Diabet Med; 2007 Aug; 24(8):906-10. PubMed ID: 17451421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of hormones on urinary incontinence in postmenopausal women.
    Quinn SD; Domoney C
    Climacteric; 2009 Apr; 12(2):106-13. PubMed ID: 19259853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Lazzeri M
    Eur Urol; 2009 Mar; 55(3):737-8. PubMed ID: 18502027
    [No Abstract]   [Full Text] [Related]  

  • 13. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen and urinary incontinence.
    Hirai K; Tsuda H
    Int J Urol; 2009 Jan; 16(1):45-8. PubMed ID: 19120525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
    Lethaby AE; Vollenhoven BJ
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A; Clowes JA; Pereda CA; Eastell R
    Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo properties of the urinary bladder wall and their modulation by estradiol and raloxifene in a rat model.
    Schultens A; Becker T; Balmer D; Seidlová-Wuttke D; Wuttke W
    Exp Clin Endocrinol Diabetes; 2004 Oct; 112(9):514-9. PubMed ID: 15505759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene: bone and cardiovascular effects.
    Francucci CM; Romagni P; Boscaro M
    J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.